<?xml version="1.0" encoding="iso-8859-1"?>
<?xml-stylesheet type="text/xsl" href="http://www.physorg.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0">
<channel>
<title>PHYSorg.com: PHYSorg news tagged with: clinical development</title>
<link>http://www.physorg.com/</link>
<language>en-us</language> 
<description>Physorg.com internet news portal provides the latest news on science including: Physics, Nanotechnology, Life Sciences, Space Science, Earth Science, Environment, Health and Medicine.</description>

 <item>
     <title>New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD</title>
   	 <description>While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.</description>
     <link>http://www.physorg.com/news150647377.html</link>
	 <category>Medicine &amp; Health</category>
	 <pubDate>Thu, 08 Jan 2009 14:29:37 EST</pubDate>
	 <guid isPermaLink="false">news150647377</guid>
</item>
<item>
     <title>When less is more: Brief inhibition of cancer target is effective and less toxic</title>
   	 <description>New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed. The study, published by Cell Press in the December issue of the journal Cancer Cell, is likely to have a major impact on the future design and implementation of targeted cancer therapies.</description>
     <link>http://www.physorg.com/news147967201.html</link>
	 <category>Medicine &amp; Health</category>
	 <pubDate>Mon, 08 Dec 2008 14:00:01 EST</pubDate>
	 <guid isPermaLink="false">news147967201</guid>
</item>


</channel>
</rss>

